Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

• Despite raising its 2026 outlook, CEO Mike Doustdar declined to provide 2027 guidance, citing factors that could support or weigh on next year's sales, leaving investors without a firm view of growth beyond 2026.
• Deutsche Bank reiterated a sell rating on Novo Nordisk shares while raising its price target, citing pricing pressure and weakness in diabetes products as ongoing risks, along with impairment charges that weighed on reported operating profit.
• The stock has a consensus rating of "Hold" from analysts, with an average price target of $59.44, but the current stock price of $40.29 is significantly below the 52-week high of $64.16, reflecting a substantial decline in value over the past year.
• Short interest in Novo Nordisk increased by 18.38% month-over-month to 37,436,108 shares as of October 15, 2026, indicating growing bearish sentiment among traders.
• Novo Nordisk's profit margin has tightened, with net income reaching DKK 16,740m on revenue of DKK 79,195m in Q3 2026, suggesting that cost pressures or pricing challenges may be impacting profitability despite strong sales.